The GNB3 C825T polymorphism affects response to HCV therapy with pegy1ated interferon in HCV/HIV co-infected but not in HCV mono-infected patients
The GNB3 C825T polymorphism affects response to HCV therapy with pegy1ated interferon in HCV/HIV co-infected but not in HCV mono-infected patients
复制标题
DOI：
10.1016/j.jhep.2007.04.008
复制
发表时间：
2007-09-01
影响因子：
25.7
通讯作者：
Nattermann, Jacob
中科院分区：
文献类型：
--
作者：
Ahlenstiel, Golo;Nischalke, Hans Dieter;Nattermann, Jacob
背景/目的：聚乙二醇化干扰素-α对丙型肝炎病毒治疗的反应是不同的，但可能至少部分取决于遗传宿主因素。G蛋白β3单位(GNB3)C825T多态已被证明影响丙型肝炎病毒单一感染的治疗反应。在这里，我们分析了GNB3基因在丙型肝炎病毒/艾滋病病毒混合感染中的影响。方法：接受聚乙二醇化干扰素/利巴韦林治疗的112例艾滋病毒/丙型肝炎病毒混合感染患者和150例丙型肝炎病毒单一感染患者进入本研究。此外，我们分析了220名健康患者和92名HIV单一感染患者。结果：HIV/丙型肝炎混合感染者与HIV阳性/丙型肝炎病毒阴性(P=0.0002.0 5)和健康对照(P=0.0 3)的GNB3型分布有显著差异。携带GNB3CC基因的患者与非CC基因携带者相比，SVR发生率显著降低(52%对77%；p=0.018)。在Logistic回归分析中，GNB3型和丙型肝炎病毒基因型与治疗反应显著相关(p=0.018)。结论：GNB3 825 CC基因型与HIV/丙型肝炎病毒混合感染患者的SVR率较低相关。这强调了遗传宿主因素对治疗反应的影响。(C)2007年欧洲肝脏研究协会。爱思唯尔出版，版权所有。
Background/Aims: Response to HCV treatment with pegylated interferon-alpha is variable but might at least in part depend on genetic host factors. The G protein beta 3 unit (GNB3) C825T polymorphism has been shown to affect treatment response in HCV mono-infection. Here, we analyzed the impact of the GNB3 genotype in the context of HCV/HIV co-infection.Methods: HIV/HCV co-infected (n = 112) and HCV mono-infected patients (n = 150), receiving therapy with pegylated IFN-alpha/ribavirin, were enrolled into this study. Furthermore, we analyzed 220 healthy and 92 HIV mono-infected patients. GNB3 genotype was defined and correlated with respect to treatment response.Results: GNB3 genotype distribution differed significantly between HIV/HCV co-infected patients and HIV-positive/HCV-negative (p = 0.0002) or healthy controls (p = 0.03). Patients with a GNB3 CC genotype had significantly lower SVR rates as compared to carriers of a non-CC genotype (52% versus 77%; p = 0.018). In a logistic regression analysis the GNB3 genotype and the HCV genotype were significantly associated with response to treatment (p = 0.018). In contrast to HIV/HCV co-infected patients, GNB3 genotype did not affect response to treatment in HCV mono-infected patients.Conclusions: The GNB3 825 CC genotype is associated with poor SVR rates in HIV/HCV co-infected patients. This underlines the impact of genetic host factors for treatment response. (C) 2007 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.